
Unlocking Bioprocessing Success: Repligen’s Market-Defying Momentum
Repligen Corp exceeded market expectations with a Q4 earnings per share of 44 cents, against a projected 41 cents, despite earnings experiencing a slight dip. Sales were steady at $167.55 million, maintaining growth compared to the previous year. The company reported a